



THE MEDICINES PATENT POOL : FACILITATING ACCESS TO HIV MEDICINES THROUGH LICENSING AND PATENT POOLING

Esteban Burrone, Head of Policy, MPP

Seminar on Philantropy and Intellectual Property – March 2015



INTRODUCTION

- Debates on Patents, Innovation and Access to Medicines have been at the center of IP policy discussions for many years
- How to maintain the incentives for **innovation** in pharmaceuticals while promoting widespread **access** to new medicines?
- Can **socially responsible licensing** be used as a collaborative mechanism to address major public health challenges such as HIV?
- **Patent pooling** has been widely used in other industries. What is its role in pharmaceuticals?




In 2008, the **WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property** recommended:

“ developing possible new mechanisms to promote transfer of and access to key health-related technologies:

(a) examine the feasibility of voluntary patent pools of upstream and downstream technologies to promote innovation of and access to health products and medical devices







The Medicines Patent Pool: a voluntary licensing mechanism





Established in 2010 with the support of













 **Terms and Conditions in MPP Licences**

“Agreements under the Medicines Patent Pool cover the broadest geographic scope and include the largest degree of flexibility for licensees” ... “Licensing activity, as well as the transparency and flexibility of terms and conditions, is highest when a third-party broker is involved, namely the Medicines Patent Pool...The Index encourages all companies engaged in Voluntary Licensing to meet the high standards demonstrated in the MPP agreements...”


Source: [The Access to Medicines Index \(2014\)](#)







NEW APPROACHES TO ENSURE INDUSTRY PARTNERSHIP

- Tiered Royalties (e.g. GDP per capita, disease burden)
- Market Segmentation (public/private)
- Product Segmentation (HIV/Non HIV use)
- Hybrid agreements (price & licensing)


ACHIEVEMENTS TO-DATE

- Licences signed for **12 priority HIV medicines**, including WHO preferred first-line treatment for both adults and children, some 2nd line medicines and promising new treatments like dolutegravir and tenofovir alafenamide
- 10 ARV sub-licence manufacturers**. Now have 52 development projects.
- MPP launched **Paediatric HIV Treatment Initiative** with UNITAID, DNDI, CHAI which aims at developing 3-6 new FDCs for children.
- MPP work expected to yield USD 1.18-1.4 billion in savings to the international community from its licences





medicines
patent
pool

NEW FRONTIERS: TB/HCV

- Currently, the MPP is conducting feasibility studies on whether its model can be used for **Hepatitis C** and **Tuberculosis**
- Potential opportunities for this model in other areas? Antimicrobial resistance?



medicines
patent
pool

MEDICINES PATENT POOL

WWW.MEDICINESPATENTPOOL.ORG